Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

7.84USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$7.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
192,102
52-wk High
$51.60
52-wk Low
$4.01

Latest Key Developments (Source: Significant Developments)

Novavax Reaches Agreement With FDA On Late Stage Trial Design For Nanoflu
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Novavax Inc ::NOVAVAX REACHES AGREEMENT WITH THE FDA ON PIVOTAL PHASE 3 TRIAL DESIGN FOR NANOFLU.NOVAVAX REACHES AGREEMENT WITH THE FDA ON PIVOTAL PHASE 3 TRIAL DESIGN FOR NANOFLU.NOVAVAX INC - CLINICAL TRIAL EXPECTED TO INITIATE IN FALL OF 2019.NOVAVAX INC - TOP-LINE CLINICAL DATA EXPECTED IN Q1 OF 2020.NOVAVAX INC - RECEIVED INPUT FROM U.S. FDA ON END-OF PHASE 2 QUESTIONS, REACHED AGREEMENT ON PHASE 3 TRIAL DESIGN FOR NANOFLU.  Full Article

Novavax To Utilize Accelerated Approval Pathway For Licensure For Nanoflu
Thursday, 27 Jun 2019 

June 27 (Reuters) - Novavax Inc ::NOVAVAX SAYS WILL UTILIZE ACCELERATED APPROVAL PATHWAY FOR LICENSURE FOR NANOFLU, ITS NANOPARTICLE SEASONAL INFLUENZA VACCINE CANDIDATE.NOVAVAX - EXPECTS TO INITIATE PIVOTAL PHASE 3 CLINICAL TRIAL FOR NANOFLU BY FALL OF 2019 WITH TOP-LINE CLINICAL DATA EXPECTED IN Q1 2020.NOVAVAX - WILL CONDUCT END-OF-PHASE 2 MEETING WITH FDA IN Q3 2019 TO DISCUSS PROPOSED PHASE 3 CLINICAL TRIAL DESIGN FOR NANOFLU.  Full Article

Novavax Q1 Loss Per Share $0.11
Thursday, 2 May 2019 

May 2 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.Q1 REVENUE $4.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.9 MILLION.NOVAVAX - AS OF MARCH 31, 2019, HAD $108.7 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES & RESTRICTED CASH, VERSUS $103.9 MILLION AS OF DEC 31, 2018.  Full Article

Novavax Reports Q1 Loss Per Share $0.11
Thursday, 2 May 2019 

May 2 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 REVENUE $4.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.  Full Article

Novavax Reports Q4 Loss Per Share $0.13
Monday, 18 Mar 2019 

March 18 (Reuters) - Novavax Inc ::NOVAVAX REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.13.Q4 REVENUE $6.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $7.1 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.NOVAVAX - AS OF DEC 31, 2018, HAD $103.9 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH, VERSUS $186.4 MILLION AS OF DEC 31, 2017.  Full Article

Novavax Q3 Revenue $7.7 Mln Vs I/B/E/S View $9.4 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Novavax Inc ::NOVAVAX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.Q3 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $7.7 MILLION VERSUS I/B/E/S VIEW $9.4 MILLION.ON TRACK TO MEET 2018 OBJECTIVES.AS OF SEPT 30, CO HAD $145.6 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH.  Full Article

Novavax Says Co And Cadila Pharmaceuticals Entered Agreement To Permit CPLB To Develop Some Cadila Biological Products
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Novavax Inc ::NOVAVAX - ON JULY 18, CO AND CADILA PHARMACEUTICALS ENTERED INTO SECOND AMENDED, RESTATED JOINT VENTURE AGREEMENT FOR CPL BIOLOGICALS PRIVATE LIMITED.NOVAVAX - PURSUANT TO AGREEMENT, CO, CADILA AMENDED AND RESTATED CERTAIN TERMS RELATED TO FIRST AMENDED AND RESTATED JOINT VENTURE AGREEMENT FOR CPLB.NOVAVAX - AGREEMENTS PERMIT CPLB TO DEVELOP SOME CADILA BIOLOGICAL PRODUCTS & TO DEVELOP CERTAIN PRODUCTS USING CO'S NANOPARTICLE VACCINE PRODUCTION.NOVAVAX-AGREEMENTS PERMIT CPLB TO DEVELOP SOME CADILA BIOLOGICAL PRODUCTS USING CO'S ANTIGEN SPECIFIC SEED DEVELOPMENT, PROTEIN EXPRESSION, OTHERS.  Full Article

Novavax Inc Promotes John Trizzino To CFO Role
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Novavax Inc ::NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER.NOVAVAX - TRIZZINO HAS BEEN SERVING AS SVP, COMMERCIAL OPERATIONS, SINCE 2014.  Full Article

Novavax Inc Q4 Loss Per Share $0.16
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Novavax Inc ::NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.16.Q4 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE $10.4 MILLION VERSUS $5.4 MILLION.Q4 REVENUE VIEW $8 MILLION -- THOMSON REUTERS I/B/E/S.JOHN J. TRIZZINO APPOINTED CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER.  Full Article

Novavax CEO Stanley Erck reports open market purchase of 100,000 co's common shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Novavax Inc :Novavax Inc says CEO Stanley Erck reports open market purchase of 100,000 co's common shares at average price of $1.13per share on november 9 - sec filing.  Full Article

UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial

June 14 Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.